Bryan, Garnier & Co acts as Independent Financial Advisor to the Supervisory Board of ITM on its senior secured term loan financing of up to $262.5m

Mai 29, 2025

ITM is a vertically integrated biotechnology company dedicated to delivering the promise of radiopharmaceuticals to patients.

Over the last 20 years, ITM developed its business to encompass every stage of the process: beginning with the production of radioisotopes and expanding to develop its own radiopharmaceuticals for diagnosis and treatment.

The company’s lead asset, n.c.a. 177Lu-edotreotide, recently met the primary endpoint in the COMPETE Phase 3 study as a potential treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM plans to submit a New Drug Application (NDA) for this asset to the U.S. FDA in 2025.

Bryan, Garnier & Co acts as Independent Financial Advisor to the Supervisory Board of ITM on its senior secured term loan of up to $262.5 million.

The capital will be used to prepare for commercial readiness and potential market launch of the company’s lead candidate, n.c.a. 177 Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide). In addition, the company will continue to accelerate the development of its innovative targeted radiopharmaceutical pipeline and the scale-up of Actinium-225 manufacturing through its joint venture, Actineer.

The transaction furthers Bryan, Garnier & Co’s track record as a leader in supporting European healthcare businesses in securing transformative debt financings to promote their growth.

„Bryan Garnier’s independent, hands-on advice and deep understanding of the debt markets were instrumental in guiding our supervisory board through a critical financing decision proposed and worked out by our executive team. BGs ability to navigate complex documentation, and to provide expert guidance supported us in assessing a bespoke financing solution that supports ITMs near-term clinical objectives while preserving long-term strategic flexibility. We greatly appreciated their integrity, experience, and commitment to acting in our best interests throughout the process“

— Udo J Vetter, Chairman, ITM

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. ITM aims to meet the needs of cancer patients, clinicians and its partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all it does, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging its two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

With $273 billion in assets under management as of March 31, 2025, Blue Owl invests across three multi-strategy platforms: Credit, GP Strategic Capital, and Real Assets. Anchored by a strong permanent capital base, it provides businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation.